0000000000118205

AUTHOR

Anita Thomas

showing 4 related works from this author

Telemedicine Online Visits in Urology During the COVID-19 Pandemic-Potential, Risk Factors, and Patients' Perspective.

2020

The current coronavirus disease 2019 (COVID-19) pandemic has placed considerable strain on hospital resources. We explored whether telemedicine (defined as a videoconference) might help. We undertook prospective structured phone interviews of urological patients (n = 399). We evaluated their suitability for telemedicine (judged by a panel of four physicians) and their risks from COVID-19 (10 factors for a poor outcome), and collected willingness for telemedicine and demographic data. Risk factors for an adverse outcome from COVID-19 infection were common (94.5% had one or more) and most patients (63.2%) were judged suitable for telemedicine. When asked, 84.7% of patients wished for a teleme…

medicine.medical_specialtyTelemedicineUrologic NeoplasmsCoronavirus disease 2019 (COVID-19)UrologyPneumonia Viral030232 urology & nephrologyUrologySubgroup analysisTelehealthMedical Oncology03 medical and health sciencesBetacoronavirus0302 clinical medicineRisk FactorsPandemicOutpatientsDisease Transmission InfectiousMedicineHumansMedical diagnosisPandemicsRemote Consultationbusiness.industrySARS-CoV-2Remote ConsultationCOVID-19Odds ratioTelemedicine030220 oncology & carcinogenesisbusinessCoronavirus InfectionsEuropean urology
researchProduct

Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.

2019

To compare toxicity and response of docetaxel chemotherapy between metastatic hormone-sensitive prostate cancer (mHSPC) and castration-resistant metastatic prostate cancer (mCRPC) patients of the same therapeutic era for assessing of upfront docetaxel against the benchmark of docetaxel in the castrate resistant stage in the setting outside of clinical trials.A prospectively collected database of real-world prostate cancer patients receiving docetaxel was divided in mHSPC and mCRPC cases and retrospectively analyzed. Principal objectives were toxicity measured by the common criteria of adverse events terminology and response characterized by Prostate specific antigen decline and radiographic…

OncologyMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsUrologymedicine.medical_treatment030232 urology & nephrologyAntineoplastic AgentsDocetaxelSeverity of Illness Index03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineHumansProspective StudiesStage (cooking)Adverse effectAgedNeoplasm StagingRetrospective StudiesChemotherapyPerformance statusbusiness.industryProstateMiddle AgedProstate-Specific Antigenmedicine.diseasePrognosisProgression-Free SurvivalClinical trialRadiographyProstate-specific antigenProstatic Neoplasms Castration-ResistantOncologyDocetaxelClinical Trials Phase III as Topic030220 oncology & carcinogenesisDisease ProgressionKallikreinsbusinessmedicine.drugUrologic oncology
researchProduct

The timing of initial imaging in testicular cancer: impact on radiological findings and clinical decision making

2021

Background In testicular cancer determination of clinical stage and recommendation of therapeutic strategy after inguinal orchiectomy are based on primary imaging by CT-scan of the chest and CT- or MRI- abdomen. It has not been investigated so far, whether the imaging should be performed before or after primary testicular surgery. Staging before surgery means exposing all patients to CT radiation irrespective of ensured histologic malignancy while postoperative staging could pose a risk in biased clinical decision making by increased presence of unspecific lymph node enlargement caused by postsurgical effects. Therefore, we aimed to investigate the association between the timing of initial …

2748 UrologyMalemedicine.medical_specialtyUrologymedicine.medical_treatmentClinical Decision-Making610 Medicine & health2700 General MedicineMalignancyTesticular NeoplasmsmedicineHumansStage (cooking)Lymph nodeTesticular cancerNeoplasm StagingRetrospective StudiesInguinal orchiectomy2727 Nephrology10042 Clinic for Diagnostic and Interventional Radiologybusiness.industrymedicine.diseasemedicine.anatomical_structureNephrologyLymphatic MetastasisRadiological weaponCohortAbdomenRadiologybusinessMinerva Urology and Nephrology
researchProduct

Risk factors and molecular characterization of penile cancer

2020

Purpose of review To provide a comprehensive summary of risk factors, molecular machinery as well as potential therapeutic targets with a particular focus on literature published in the last 2 years on prognosis and treatment of penile cancer (PeCa). Recent findings E2F, LAMC2, MAML2, ID1 and IGFBP2 proteins were demonstrated to play a critical role for aggressive tumor behavior and might predict poor survival in PeCa. PD-L1 axis was confirmed as a promising pathway to serve as a therapeutic target. A number of genetic alterations were illuminated. In clinical testing, pan-HER tyrosine kinase inhibitor dacomitinib provided promising results in chemo-naive and EGFR monoantibody nimotuzumab i…

Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classUrology030232 urology & nephrologyIndividualized treatmentmedicine.diseaseSystemic therapyDacomitinibTyrosine-kinase inhibitorClinical trial03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisInternal medicineMonoclonalmedicineNimotuzumabPenile cancerbusinessmedicine.drugCurrent Opinion in Urology
researchProduct